Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  CNS drug reviews

• Publication date

  2006-06-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1527-3458.2001.TB00205.XPMID 11830755PMCID PMC6741646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetics of cholinesterase inhibition by eptastigmine in man

  2004cited by this paper
• Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

  2004cited by this paper
• Excitatory and inhibitory effects of second-generation cholinesterase inhibitors on rat gastrointestinal transit.

  2000cited by this paper
• Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats.

  2000cited by this paper
• Eptastigmine improves eight-arm radial maze performance in aged rats.

  2000cited by this paper
• A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease

  2000cited by this paper
• Cannabinoid‐induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats

  2000cited by this paper
• Eptastigmine restores the aged rat's normal cortical spectral power pattern.

  2000cited by this paper
• Treatment of Alzheimer's disease.

  1999cited by this paper
• Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease

  1999cited by this paper
• Effects of Cholinergic Drugs on Neocortical EEG and Flash-Visual Evoked Potentials in the Mouse

  1999cited by this paper
• Protection of mice against soman by pretreatment with eptastigmine and physostigmine.

  1999cited by this paper
• Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication.

  1999cited by this paper
• Two-Year Treatment of Alzheimer’s Disease with Eptastigmine

  1999cited by this paper
• Invited Review Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications

  1998cited by this paper
• Effect of food on the absorption of eptastigmine

  1998cited by this paper
• Effect of the subchronic treatment with the acetylcholinesterase inhibitor heptastigmine on central cholinergic transmission and memory impairment in aged rats.

  1998cited by this paper
• A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.

  1998cited by this paper
• Eptastigmine

  1998cited by this paper
• Cholinergic foundations of Alzheimer's disease therapy.

  1998cited by this paper
• Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

  1998cited by this paper
• Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers

  1998cited by this paper
• Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease

  1997cited by this paper
• Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex.

  1997cited by this paper
• From molecular structure to Alzheimer therapy.

  1997cited by this paper
• α2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat

  1996cited by this paper
• Phosphotriesterase, pralidoxime-2-chloride (2-PAM) and eptastigmine treatments and their combinations in DFP intoxication.

  1996cited by this paper
• An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.

  1996cited by this paper
• Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease

  1996cited by this paper
• Effects of MF‐268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex

  1996cited by this paper
• Eptastigmine-phosphotriesterase combination in DFP intoxication.

  1996cited by this paper
• The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis.

  1995cited by this paper
• Cholinergic modulation of a decrement in social investigation following repeated contacts between mice

  1995cited by this paper
• Transdermal Delivery of Cholinesterase Inhibitors

  1995cited by this paper
• A Patient‐Side Technique for Real‐Time Measurement of Acetylcholinesterase Activity During Monitoring of Eptastigmine Treatment

  1995cited by this paper
• The Target Population in Phase I Clinical Trials of Cholinergic Compounds in Alzheimer Disease: The Role of the “Bridging Study”

  1995cited by this paper
• Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

  1995cited by this paper
• Coadministration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo.

  1995cited by this paper
• Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers

  1995cited by this paper
• Alzheimer disease : therapeutic strategies

  1994cited by this paper
• A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.

  1994cited by this paper
• Eptastigmine (MF-201). A Double-Blind, Placebo-Controlled, Clinical Trial in Alzheimer Disease Patients

  1994cited by this paper
• Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain.

  1994cited by this paper
• Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo.

  1994cited by this paper
• Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.

  1993cited by this paper
• The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.

  1993cited by this paper
• Effect of acute and short-term administration of cholinomimetic drugs on corticosterone secretion in the rat.

  1993cited by this paper
• Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats

  1993cited by this paper
• Rapid potentiometric determination of cholinesterases in plasma and red cells: application to eptastigmine monitoring.

  1993cited by this paper
• Approaches to cholinergic therapy in Alzheimer's disease.

  1993cited by this paper
• Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection.

  1993cited by this paper
• Alzheimer's disease--from molecular biology to therapy.

  1993cited by this paper
• Chapter 51: Approaches to cholinergic therapy in Alzheimer's disease

  1993cited by this paper
• A double‐blind, placebo‐controlled study of the effects of eptastigmine on scopolamine‐induced cognitive deficits in healthy male subjects

  1993cited by this paper
• Heptyl‐physostigmine enhances basal forebrain control of cortical cerebral blood flow

  1992cited by this paper
• Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).

  1992cited by this paper
• The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.

  1992cited by this paper
• Preferential inhibition of acetylcholinesterase molecular forms in rat brain

  1992cited by this paper
• Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection.

  1992cited by this paper
• Profile of cholinomimetic drugs in primates: Status of screens for potential Alzheimer therapies

  1992cited by this paper
• Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.

  1992cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• Pharmacokinetics of heptastigmine in rats.

  1992cited by this paper
• Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain.

  1992cited by this paper
• The Second Generation of Cholinesterase Inhibitors: Clinical and Pharmacological Effects

  1991cited by this paper
• The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.

  1991cited by this paper
• The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat

  1989cited by this paper
• A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.

  1987cited by this paper
• Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.

  1986cited by this paper

• The effect of acetylcholinesterase inhibitor rivastigmine in pentylenetetrazole-induced kindling model of epilepsy in rats

  2024cites this paper
• Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.

  2024cites this paper
• Toxicity of Glycyl-l-Prolyl-l-Glutamate Pseudotripeptides: Cytotoxic, Oxidative, Genotoxic, and Embryotoxic Perspectives

  2022cites this paper
• Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities

  2021cites this paper
• Applications of phytochemicals against nerve agents in counterterrorism

  2021cites this paper
• Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates

  2020cites this paper
• Acetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future

  2020cites this paper
• Arctium lappa L. root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells.

  2019cites this paper
• Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.

  2018cites this paper
• (R)-α-Lipoyl-Gly-l-Pro-l-Glu dimethyl ester as dual acting agent for the treatment of Alzheimer's disease.

  2017cites this paper
• The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials

  2017cites this paper
• Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs

  2017cites this paper
• Old and new acetylcholinesterase inhibitors for Alzheimer’s disease

  2016cites this paper
• Donepezil’s Effect on Cardiac Function in Patients with Alzheimer’s Disease through an In Vivo, Non Invasive Measure of Cardiac Autonomic Function

  2015cites this paper
• Lamiaceae Family Plants as a Potential Anticholinesterase Source in the Treatment of Alzheimer's Disease Alzheimer Hastaliği Tedavisinde Potansiyel Antikolinesteraz Bir Kaynak Olarak Lamiaceae Familyasi Bitkileri

  2014cites this paper
• 1 Lamiaceae Family Plants as a Potential Anticholinesterase Source in the Treatment of Alzheimer ’ s Disease Alzheimer

  2014cites this paper
• Research Strategies Developed for the Treatment of Alzheimer’s Disease. Reversible and Pseudo-Irreversible Inhibitors of Acetylcholinesterase: Structure-Activity Relationships and Drug Design

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Alkaloids and Inhibitory Effects Against Enzymes Linked to Neurodegenerative Diseases (Physostigmine, Galanthamine, Huperzine, etc.)

  2013cites this paper
• Alkaloids and Drug Discovery for Neurodegenerative Diseases

  2013cites this paper
• Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.

  2012cites this paper
• 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment.

  2011cites this paper
• The Role of Phytochemicals in the Treatment and Prevention of Dementia

  2011cites this paper
• The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques.

  2011cites this paper
• Galantamine for Alzheimer's disease

  2010cites this paper
• Traditional Medicine for Memory Enhancement

  2009cites this paper
• Cholinesterase inhibitors and beyond.

  2009cites this paper
• Acetylcholinesterase Inhibitors of Natural Origin

  2009cites this paper
• Increasing hippocampal acetylcholine levels enhance behavioral performance in an animal model of diencephalic amnesia.

  2008cites this paper
• Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease

  2008cites this paper
• Long-Term Treatment Response, Predictors and Biochemical Markers in Alzheimer's Disease

  2008cites this paper
• Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys

  2007cites this paper
• Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine

  2006cites this paper
• Analogues as a Means of Discovering New Drugs

  2006cites this paper
• Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release.

  2006cites this paper
• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

  2005cites this paper
• Spatial memory in aged rats is related to PKCgamma-dependent G-protein coupling of the M1 receptor.

  2005cites this paper
• The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.

  2005cites this paper
• Adaptive urn designs for estimating several percentiles of a dose–response curve

  2004cites this paper
• The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

  2003cites this paper